BioPharmSignal logoBioPharmSignal

Biotech News

Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics

Neurocrine Biosciences (NBIX)Neurocrine BiosciencesCommercial

Strengthens Neurocrine's rare disease portfolio with VYKAT™ XR, the first and only approved treatment for hyperphagia in Prader-Willi syndrome Adds recently launched therapy with strong early adoption and meaningful commercial potential SAN DIEGO, May 18, 2026 /PRNewswire/ -- Neurocrine

Related news

NBIXNeurocrine Biosciences2026-09-30 12:30 EST

Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference

NBIXNeurocrine Biosciences2026-09-28 20:05 EST

Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer

TNXPTonix Pharmaceuticals2026-09-22 11:00 EST

Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®

TNXPTonix Pharmaceuticals2026-09-08 11:00 EST

Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer

ECORelectroCore2026-08-03 12:00 EST

electroCore to Participate in Upcoming Investor Conferences

ALKSAlkermes plc2026-09-10 11:00 EST

Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program

GANXGain Therapeutics2026-10-01 13:28 EST

Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration

GANXGain Therapeutics2026-09-29 21:50 EST

Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders

AXSMAxsome2026-09-21 11:00 EST

Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day

AXSMAxsome2026-09-17 11:00 EST

Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026

View all latest news

Neurocrine Biosciences

Neuroscience and Endocrinology Portfolio Neurocrine Biosciences discovers, develops and commercializes medicines for neuropsychiatric, neurological, endocrine and immunological disorders. Its business combines several first-in-class commercial products with a deep mid- and late-stage pipeline. Commercial Medicines The portfolio includes...

Recent company news

NBIXNeurocrine Biosciences2026-09-30 12:30 EST

Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference

NBIXNeurocrine Biosciences2026-09-28 20:05 EST

Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer

NBIXNeurocrine Biosciences2026-09-02 20:01 EST

Neurocrine Biosciences to Present at Upcoming Investor Conferences in September

NBIXNeurocrine Biosciences2026-08-12 12:30 EST

Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia

NBIXNeurocrine Biosciences2026-08-07 12:30 EST

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist

Stock data

Close
145.51 USD
Market cap
15.57B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States